UK-ADRC neuroimaging supplement: LATE and PART

UK-ADRC 神经影像补充：LATE 和 PART

• 批准号: 10170755
• 负责人: BRIAN Timothy GOLD
• 金额: $ 36.72万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-07-15 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10170755
• 关键词: Address; African American; Alzheimer' s Disease; Alzheimer' s disease related dementia; Amyloid; Autopsy; Biological; Biological Markers; Biometry; Brain; Brain imaging; Cerebrovascular Disorders; Cessation of life; Characteristics; Clinical; Clinical Trials; Clinical assessments; Cognitive; Cognitive aging; Collection; Communities; Data; Data Set; Degenerative Disorder; Dementia; Development; Disease; Education; Education and Outreach; Elderly; Environment; Fostering; Funding; Genetic; Goals; High Prevalence; Image; Impairment; Individual; Infrastructure; Kentucky; Letters; Liquid substance; Longitudinal cohort; Magnetic Resonance Imaging; Mission; Nature; Participant; Pathogenicity; Pathologic; Pathology; Pattern; Phenotype; Protocols documentation; Research; Research Personnel; Resources; Scanning; Spectrum Analysis; Standardization; Tauopathies; Time; Translations; United States; United States National Institutes of Health; Universities; age related; aged; aging population; base; biomarker development; biomarker discovery; central database; clinical development; clinical phenotype; cohort; data management; education research; experience; hippocampal atrophy; human old age (65+); in vivo; innovation; knowledge translation; limbic-predominant age-related TDP-43 encephalopathy; longitudinal analysis; machine learning algorithm; neurochemistry; neuroimaging; neuroimaging marker; neuropathology; new therapeutic target; normal aging; novel marker; novel therapeutics; outreach; parent grant; pre-clinical; preclinical study; programs; recruit; research study; statistics; success; tau Proteins; vascular cognitive impairment and dementia; white matter

PROJECT SUMMARY/ABSTRACT – OVERALL (Adapted from Abstract of parent grant, UK-ADC) This is a proposal for a University of Kentucky Alzheimer’s Disease Research Center (UK-ADRC) neuroimaging supplement. This purpose of the supplement is to provide neuroimaging data on the UK-ADRC’s deeply phenotyped clinical cohort to the NIH’s recently funded initiative, Standardized Centralized Alzheimer's and Related Dementias Neuroimaging (SCAN). In addition, a secondary purpose of this supplement is to identify neuroimaging correlates of two AD-mimics: limbic-predominant age-related TDP-43 encephalopathy (LATE) and primary age-related tauopathy (PART). The UK-ADRC is an experienced and collaborative ADRC originally funded in 1985. Our principal mission is to serve as the focal point for all AD-related activities at UK and this region of the United States, by providing an environment and core resources that catalyze innovative research, outreach, education, and clinical programs. Our signature resources include: 1) a cognitively normal group of ~500 subjects followed longitudinally, with all committed to brain autopsy upon death; 2) a strong program in clinical-neuropathological correlations and short postmortem interval autopsies; 3) an established program studying preclinical biomarkers of AD using neuroimaging and biofluids; 4) an integrated centralized database and innovative biostatistical expertise to characterize clinical and biological transitions; and 5) a successful and close partnership with the African-American community and increased participation of underrepresented individuals in our longitudinal cohort and ADRC-affiliated research studies and clinical trials. The overall scientific emphasis of the UK-ADRC continues to be on our interrelated themes: Transitions & Translation. Our well-characterized, longitudinal cohort and historically strong neuropathology program focused on normal aging, preclinical disease states and early cognitive transitions have been central to our success in defining early pathogenic mechanisms underlying the transitions from normal cognitive aging to impairment. The depth of expertise and collaborative nature of our investigators have also resulted in substantial progress on translation of that knowledge into new targets and novel therapeutic strategies. The UK-ADRC provides an infrastructure and environment that focuses on these integrated themes and advances AD research, education, outreach, and clinical programs through highly interactive and effective components: Administrative Core, Clinical Core, Data Management and Statistics Core, Neuropathology Core, Outreach and Recruitment Core, Biomarker Core, and Research Education Component. The UK-ADRC will make resources from these Cores available to support the success of this ADRC neuroimaging supplement.

项目概要/摘要-总体（改编自母基金摘要，UK-ADC） 这是一个关于肯塔基州大学阿尔茨海默病研究中心的建议 神经影像学补充。补充的目的是提供UK-ADRC的神经影像学数据 美国国立卫生研究院最近资助的计划，标准化集中阿尔茨海默氏症， 相关痴呆神经影像学（SCAN）此外，该补充的第二个目的是 两种拟AD患者神经影像学相关性鉴定：边缘优势年龄相关TDP-43脑病 （LATE）和原发性年龄相关性tau蛋白病（PART）。UK-ADRC是一个经验丰富的合作ADRC 最初于1985年成立。我们的主要使命是成为英国所有广告相关活动的协调中心 和美国的这个地区，通过提供一个环境和核心资源， 研究、推广、教育和临床项目。我们的标志性资源包括：1）认知正常 一组约500名受试者纵向跟踪，所有人都致力于死亡后的脑尸检; 2）一个强大的 在临床神经病理学的相关性和短的死后间隔尸检程序; 3）一个既定的 使用神经成像和生物流体研究AD的临床前生物标志物的计划; 4）集成的集中式 数据库和创新的生物统计专业知识，以表征临床和生物学转变;以及5）a 与非裔美国人社区建立成功和密切的伙伴关系， 在我们的纵向队列和ADRC附属的研究和临床试验中代表性不足的个体。 UK-ADRC的整体科学重点仍然是我们相互关联的主题： 翻译.我们的特点鲜明，纵向队列和历史上强大的神经病理学计划 专注于正常衰老，临床前疾病状态和早期认知转变一直是我们研究的核心。 成功地定义了从正常认知老化到 损伤我们的调查人员的专业知识和合作性质的深度也导致了 在将这些知识转化为新的靶点和新的治疗策略方面取得了实质性进展。的 UK-ADRC提供了一个专注于这些综合主题和进展的基础设施和环境 通过高度互动和有效的组件进行AD研究，教育，推广和临床计划： 管理核心、临床核心、数据管理和统计核心、神经病理学核心、外展和 招募核心、生物标志物核心和研究教育组成部分。联合王国-ADRC将提供资源 从这些核心可用于支持这种ADRC神经影像补充的成功。

项目成果

Expression and regulation of a low-density lipoprotein receptor exon 12 splice variant.

• DOI: 10.1111/j.1471-4159.2010.06972.x
• 发表时间: 2010-11
• 期刊: Journal of neurochemistry
• 影响因子: 4.7
• 作者: Ling IF;Gopalraj RK;Simpson JF;Estus S
• 通讯作者: Estus S

Motivators for Alzheimer's disease clinical trial participation.

• DOI: 10.1007/s40520-017-0771-2
• 发表时间: 2018-03
• 期刊: Aging clinical and experimental research
• 影响因子: 4
• 作者: Bardach SH;Holmes SD;Jicha GA
• 通讯作者: Jicha GA

Comparison of behaviors characteristic of autism spectrum disorder behaviors and behavioral and psychiatric symptoms of dementia.

• DOI: 10.1080/13607863.2020.1849025
• 发表时间: 2022-03
• 期刊: Aging & mental health
• 影响因子: 3.4
• 作者: Rhodus EK;Barber J;Abner EL;Bardach SH;Gibson A;Jicha GA
• 通讯作者: Jicha GA

A Comprehensive Behavioral Test Battery to Assess Learning and Memory in 129S6/Tg2576 Mice.

• DOI: 10.1371/journal.pone.0147733
• 发表时间: 2016
• 期刊: PloS one
• 影响因子: 3.7
• 作者: Wolf A;Bauer B;Abner EL;Ashkenazy-Frolinger T;Hartz AM
• 通讯作者: Hartz AM

Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer's Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study.

• DOI: 10.3390/jcm10091907
• 发表时间: 2021-04-28
• 期刊: Journal of clinical medicine
• 影响因子: 3.9
• 作者: Hendrix JA;Airey DC;Britton A;Burke AD;Capone GT;Chavez R;Chen J;Chicoine B;Costa ACS;Dage JL;Doran E;Esbensen A;Evans CL;Faber KM;Foroud TM;Hart S;Haugen K;Head E;Hendrix S;Hillerstrom H;Kishnani PS;Krell K;Ledesma DL;Lai F;Lott I;Ochoa-Lubinoff C;Mason J;Nicodemus-Johnson J;Proctor NK;Pulsifer MB;Revta C;Rosas HD;Rosser TC;Santoro S;Schafer K;Scheidemantel T;Schmitt F;Skotko BG;Stasko MR;Talboy A;Torres A;Wilmes K;Woodward J;Zimmer JA;Feldman HH;Mobley W
• 通讯作者: Mobley W